NEXGEL Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

NEXGEL şirketinin toplam hissedar öz sermayesi $5.0M ve toplam borcu $709.0K olup, bu da borç-öz sermaye oranını 14.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $10.6M ve $5.6M dir.

Anahtar bilgiler

14.2%

Borç/özkaynak oranı

US$709.00k

Borç

Faiz karşılama oranı	n/a
Nakit	US$1.06m
Eşitlik	US$4.99m
Toplam yükümlülükler	US$5.59m
Toplam varlıklar	US$10.57m

Son finansal sağlık güncellemeleri

Recent updates

NexGel: Old Wine In A New Bottle

Jan 30

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NXGL 'nin kısa vadeli varlıkları ( $4.6M ) kısa vadeli yükümlülüklerini ( $3.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: NXGL şirketinin kısa vadeli varlıkları ( $4.6M ) uzun vadeli yükümlülüklerini ( $2.5M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NXGL şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: NXGL şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 14.2% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: NXGL şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: NXGL un, serbest nakit akışı her yıl % 18.9 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

NEXGEL Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

NEXGEL, Inc. announced delayed annual 10-K filing

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 14% to US$6.00

Forecast breakeven date moved forward to 2025

NEXGEL, Inc. has filed a Follow-on Equity Offering.

NEXGEL, Inc. to Report Q3, 2024 Results on Nov 14, 2024

NEXGEL, Inc. Appoints Kip Crecca to Its Scientific Advisory Board

NEXGEL, Inc. Reiterates Revenue Guidance for the Third Quarter and Fourth Quarter of 2024

NEXGEL, Inc. has filed a Follow-on Equity Offering in the amount of $1.11 million.

NEXGEL, Inc. to Report Q2, 2024 Results on Aug 14, 2024

New minor risk - Share price stability

NEXGEL, Inc. and Innovative Optics US Initiate Institutional Review Board Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal

NEXGEL, Inc. Provides Preliminary Revenue Guidance for the Second, Third and Fourth Quarter of 2024

Price target decreased by 14% to US$6.00

NEXGEL, Inc. to Report Q1, 2024 Results on May 13, 2024

NEXGEL, Inc., Annual General Meeting, Jun 17, 2024

NEXGEL, Inc. announced delayed annual 10-K filing

Forecast breakeven date pushed back to 2026

NEXGEL, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

NEXGEL, Inc. has filed a Follow-on Equity Offering.

NEXGEL, Inc. has filed a Follow-on Equity Offering.

NEXGEL, Inc. has filed a Follow-on Equity Offering.

NEXGEL, Inc. Announces Intention of Miranda J. Toledano to Resign as a Member of the Board of Directors, Effective as of March 31, 2024

NEXGEL, Inc. Announces Resignation of David Stefansky as Member of the Board of Directors

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

NEXGEL, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Price target increased by 20% to US$6.00

New major risk - Market cap size

New major risk - Market cap size

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

NEXGEL, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Consensus revenue estimates increase by 62%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

NEXGEL, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

NEXGEL, Inc. Announces Directorate and Committee Changes

Nexgel Appoints Scott Henry, to Board of Directors and Audit Committee

Forecast to breakeven in 2025

NEXGEL, Inc. Launches Turfguard to Treat Painful Turf Burns and Protect Sports-Related Wounds

NEXGEL, Inc. (NasdaqCM:NXGL) announces an Equity Buyback for $0.5 million worth of its shares.

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

NEXGEL, Inc. to Report Q3, 2022 Results on Nov 08, 2022

NEXGEL, Inc. Reports Positive Results from Proof-Of-Concept Study for Its Diclofenac Hydrogel Pain Treatment

Nexgel, Inc. Develops New Hydrogel Patch to Treat Amblyopia

NEXGEL, Inc. Announces SAGE Journals Publishes New Data Revealing SilverSeal Hydrogel Dressing Improves Postsurgical Scarring

NEXGEL, Inc. Announces Scientific Advisory Board Appointments

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NEXGEL, Inc. to Report Q2, 2022 Results on Aug 10, 2022

NEXGEL Launches Medagel Hydroliner Pro Pads for Eyelash Protection During Cosmetic Extensions Service

NEXGEL, Inc., Annual General Meeting, Aug 30, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

NEXGEL, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

NexGel: Old Wine In A New Bottle

NEXGEL, Inc. Announces the Launch of MEDAGEL ClearComfort Hydrogel Patch

NEXGEL, Inc. has completed an IPO in the amount of $14.235131 million.

High number of new and inexperienced directors

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin